Dr Jamie Fletcher

Tabs

Main

Contact Category:

Conjoint

Discipline:

Paediatrics

Research outline

I am a translational researcher based at the Children’s Cancer Institute, where I lead a team of postdoctoral researchers and students focused on the childhood solid tumour neuroblastoma. Children with high-risk neuroblastoma frequently relapse with incurable, drug resistant disease, resulting in long-term survival rates below 50%. We seek to understand the biology of neuroblastoma and to improve patient survival rates through:

Identifying molecular mechanisms underlying drug resistance
Developing small molecule inhibitors targeting drug resistance mechanisms, with particular focus on multidrug resistance proteins
Developing improved pre-clinical testing models for high-risk neuroblastoma, including patient-derived xenograft (PDX) models and models of metastatic disease
Modelling personalised medicine strategies, including molecular profiling and ex vivo drug sensitivity screening

My team applies high-throughput drug screening, genomic analysis, mouse models, cell biology and tissue-culture based approaches to the study of drug resistance mechanisms, personalised medicine and new drug development in high-risk neuroblastoma. Our high-risk neuroblastoma research is published in leading journals, including JNCI, Cancer Res, Oncogene, Eur J Cancer, Nature Reviews Cancer and Science Translational Medicine.

Sample publications

Kamili A, Gifford AJ, Li N, Mayoh C, Chow SO, Failes TW, Eden GL, Cadiz R, Xie J, Lukeis RE, Norris MD, Haber M, McCowage GB, Arndt GM, Trahair TN, Fletcher JI (2020) Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. British Journal of Cancer Jan 10, 2020. doi: 10.1038/s41416-019-0682-4.

Koach J, Holien JK, …24 authors…Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. Cancer Research 79(21):5652-5667.

Huynh T, Murray J, Flemming CL, Kamili A, Hofmann U, Cheung L, Roundhill EA, Yu DMT, Webber HT, Schwab M, Henderson MJ, Haber M, Norris MD, Fletcher JI. (2019) CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. Biochemical Pharmacology 172:113770.

Gana CC, Hanssen KM, Yu DM, Flemming CL, Wheatley MS, Conseil G, Cole SPC, Norris MD, Haber M, Fletcher JI (2019) MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochemical Pharmacology 168:237-248.

Gamble LD…24 authors…Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M (2019) Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine 11 (477), eaau1099.

Fletcher JI, Ziegler DS, Trahair TN, Marshall GM, Haber M, Norris MD. (2018) Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nature Reviews Cancer 18(6):389-400

Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI (2017) Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumor growth and sensitizes to irinotecan in vivo European Journal of Cancer 83:132-141.

Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers (2017) Cancer Research 77(4):971-981

O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, von Jonquieres G, Pickett HA, London WB, Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL. (2016) MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin Cancer Research 76(12):3604-17.

Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, Marshall GM, Haber M, *Fletcher JI, *Ashton LJ (2015) MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Oncotarget 6:15510-23.

Cheung L, Yu DM, Neiron Z, Failes TW, Arndt GM, Fletcher JI (2015) Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen. Biochemical Pharmacology 93:380-8.

Cheung L, Flemming CL, Watt F, Masada N, Yu DM, Huynh T, Conseil G, Tivnan A, Polinsky A, Gudkov AV, Munoz MA, Vishvanath A, Cooper DM, Henderson MJ, Cole SP, Fletcher JI, Haber M, Norris MD. (2014) High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology 91:97-108.

Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, London WB, Marshall GM, Norris MD, Perini G, Haber M (2012) N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. Cancer Research 72(4):845-853.

Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer 10, 147-56.

Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DCS, Adams JM (2008) Apoptosis is triggered when pro-survival Bcl-2 proteins cannot restrain Bax. Proceeding of the National Academy of Sciences USA 105, 18081-18087.

Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859.

School:

Sch Women's&Children's Health

Phone:

9385 1579

Email:

JFletcher@ccia.unsw.edu.au

University role:

Conjoint Senior Lecturer

Qualifications:

Bachelor of Medical Science (Hons.), University of Sydney

PhD, University of Sydney

Grants:

Current research support

NHMRC Ideas Grant; 2020–2021; Improving induction therapy for high-risk neuroblastoma through bypass or inhibition of P-glycoprotein (APP1182974)

Children’s Cancer Foundation; 2019–2022; Leveraging the SIOPEN High risk 2.0 clinical trial for high-risk neuroblastoma to understand relapse, improve residual disease detection and develop pre-clinical testing models for high-risk neuroblastoma

NHMRC Project Grant; 2018–2020; Precision medicine for high-risk neuroblastoma (APP1146817)

NHMRC Development Grant; 2018–2020; Multidrug Resistance Protein 1 inhibitors to sensitise cancers to chemotherapy (APP1136278)

Neuroblastoma Australia; 2018–2020; Characterization of high-risk neuroblastoma models to support translational research

Neuroblastoma Australia; 2018–2019; Optimization of high-risk neuroblastoma model development

Awards:

UNSW ARC Postgraduate Council Supervisor Award 2018

UNSW Faculty of Medicine Dean’s Rising Star Award 2011

Children's Cancer Institute Award 2011

Cancer Institute NSW Career Development & Support Fellowship 2010

Balnaves Foundation Young Researcher’s Fund Award 2008

NHMRC Peter Doherty Fellowship 2000

Keywords:

cancer

paediatric oncology

multidrug resistance

anticancer drug development

personalised medicine

animal models

preclinical drug evaluation

neuroblastoma

tumour biology

circulating tumor cell

drug screening assays

personalised medicine

Research

Socio-economic Objective (SEO) tags:

Cancer and Related Disorders

Field of Research (FOR) Tag:

Cancer Cell Biology

Teaching & Supervision

I am available to supervise:

Yes

Areas of supervision:

Potential honours and PhD projects

Inhibition of Multidrug Resistance Proteins as a therapeutic strategy in paediatric and adult cancers
Modelling personalised medicine strategies in high-risk neuroblastoma

Supervision keywords:

cancer

nervous system cancers

drug resistance

anticancer drugs

Media

Facebook:

https://www.facebook.com/UNSWWomensChildrensHealth/

Publications related to this Person

Book Chapters

Fletcher J; Roundhill E; Haber M; Norris M, 2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52

Fletcher JI; Haber M; Henderson M; Norris MD, 2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, edn. Pediatric Cancer-Diagnosis Therapy and Prognosis, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11

Journal articles

Le Grand M; Kimpton K; Gana CC; Valli E; Valli E; Fletcher JI; Kavallaris M; Kavallaris M, 2020, 'Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma', ACS Pharmacology and Translational Science, vol. 3, pp. 148 - 160, http://dx.doi.org/10.1021/acsptsci.9b00085

Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, vol. 172, http://dx.doi.org/10.1016/j.bcp.2019.113770

Kamili A; Atkinson C; Trahair TN; Fletcher JI, 2020, 'Mouse models of high-risk neuroblastoma', Cancer and Metastasis Reviews, http://dx.doi.org/10.1007/s10555-020-09855-0

Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-019-0682-4

Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, vol. 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112

Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, vol. 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009

Boutros R; Catchpoole D; Collins K; Cross S; Downie P; Drinkwater C; Fletcher J; Gottardo N; Hunter S; Kirby M; Ludlow L; MacNish M; Maybury M; Moore A; Morrin H; Purdy S; Revesz T; Saffery R; Strong R; Trahair T; Wood A; Byrne J, 2019, 'The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network', Biopreservation and Biobanking, vol. 17, pp. 95 - 97, http://dx.doi.org/10.1089/bio.2019.0013

Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, vol. 11, http://dx.doi.org/10.1126/scitranslmed.aau1099

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, vol. 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, vol. 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024

Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, vol. 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906

O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL, 2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, vol. 76, pp. 3604 - 3617, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879

Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, vol. 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004

Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, vol. 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001

Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, vol. 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675

Cheung L; Yu DMT; Neiron Z; Failes TW; Arndt GM; Fletcher JI, 2015, 'Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen', Biochemical Pharmacology, vol. 93, pp. 380 - 388, http://dx.doi.org/10.1016/j.bcp.2014.11.006

Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, vol. 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732

Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DMF; Henderson MJ; Cole SPC; Fletcher JI; Haber M; Norris MD, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, vol. 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023

Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M, 2014, 'RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model', Oncogene, vol. 33, pp. 882 - 890, http://dx.doi.org/10.1038/onc.2013.11

Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M, 2012, 'N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma', Cancer Research, vol. 72, pp. 845 - 853, http://dx.doi.org/10.1158/0008-5472.CAN-11-1885

Henderson M; Haber M; Porro A; Munoz M; Xue C; Murray JE; Flemming C; Smith J; Fletcher JI; Gherardi S; Kwek C; Russell AJ; Valli E; London WB; Buxton AB; Ashton LJ; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Norris MD, 2011, 'ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux', Journal of the National Cancer Institute, vol. 103, pp. 1236 - 1251, http://dx.doi.org/10.1093/jcni/djr256

Kvansakul M; Wei AH; Fletcher JI; Willis SN; Chen L; Roberts AW; Huang DCS; Colman PM, 2010, 'Structural basis for apoptosis inhibition by Epstein-Barr virus bhrf1', PLoS Pathogens, vol. 6, http://dx.doi.org/10.1371/journal.ppat.1001236

Fletcher JI; Haber M; Henderson M; Norris MD, 2010, 'ABC transporters in cancer: more than just drug efflux pumps', Nature Reviews Cancer, vol. 10, pp. 147 - 156, http://dx.doi.org/10.1038/nrc2789

Branson KM; Mertens HDT; Swarbrick JD; Fletcher JI; Kedzierski L; Gayler KR; Gooley PR; Smith BJ, 2009, 'Discovery of Inhibitors of Lupin Diadenosine 5 ',5 '''-P-1,P-4-Tetraphosphate Hydrolase by Virtual Screening', BIOCHEMISTRY, vol. 48, pp. 7614 - 7620, http://dx.doi.org/10.1021/bi900813x

Fletcher JI; Meusburger S; Hawkins CJ; Riglar DT; Lee EF; Fairlie WD; Huang DCS; Adams JM, 2008, 'Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 18081 - 18087, http://dx.doi.org/10.1073/pnas.0808691105

Fletcher JI; Huang DCS, 2008, 'Controlling the cell death mediators Bax and Bak - Puzzles and conundrums', CELL CYCLE, vol. 7, pp. 39 - 44, http://dx.doi.org/10.4161/cc.7.1.5178

Mason KD; Carpinelli MR; Fletcher JI; Collinge JE; Hilton AA; Ellis S; Kelly PN; Ekert PG; Metcalf D; Roberts AW; Huang DCS; Kile BT, 2007, 'Programmed Anuclear Cell Death Delimits Platelet Life Span', Cell, vol. 128, pp. 1173 - 1186, http://dx.doi.org/10.1016/j.cell.2007.01.037

Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DCS, 2007, 'Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak', SCIENCE, vol. 315, pp. 856 - 859, http://dx.doi.org/10.1126/science.1133289

Fletcher JI; Huang DCS, 2006, 'BH3-only proteins: orchestrating cell death', CELL DEATH AND DIFFERENTIATION, vol. 13, pp. 1268 - 1271, http://dx.doi.org/10.1038/sj.cdd.4401995

Willis SN; Chen L; Dewson G; Wei A; Naik E; Fletcher JI; Adams JM; Huang DCS, 2005, 'Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x(L), but not Bcl-2, until displaced by BH3-only proteins', GENES & DEVELOPMENT, vol. 19, pp. 1294 - 1305, http://dx.doi.org/10.1101/gad.1304105

Voskoboinik I; Thia MC; Fletcher J; Ciccone A; Browne K; Smyth MJ; Trapani JA, 2005, 'Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain', JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, pp. 8426 - 8434, http://dx.doi.org/10.1074/jbc.M413303200

Chen L; Willis SN; Wei A; Smith BJ; Fletcher JI; Hinds MG; Colman PM; Day CL; Adams JM; Huang DCS, 2005, 'Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function', MOLECULAR CELL, vol. 17, pp. 393 - 403, http://dx.doi.org/10.1016/j.molcel.2004.12.030

Swarbrick JD; Buyya S; Gunawardana D; Fletcher JI; Branson K; Smith B; Pepe S; McLennan A; Gayler KR; Gooley PR, 2005, 'Letter to the Editor: H-1, C-13, and N-15 resonance assignments of the 17 kDa Ap4A hydrolase from Homo sapiens in the presence and absence of ATP', JOURNAL OF BIOMOLECULAR NMR, vol. 31, pp. 181 - 182, http://dx.doi.org/10.1007/s10858-004-7440-4

Adams JM; Huang DCS; Strasser A; Willis S; Chen L; Wei A; Van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S, 2005, 'Subversion of the Bcl-2 life/death switch in cancer development and therapy', Molecular Approaches to Controlling Cancer, vol. 70, pp. 469 - 477, http://dx.doi.org/10.1101/sqb.2005.70.009

de Planque MRR; Rijkers DTS; Fletcher JI; Liskamp RMJ; Separovic F, 2004, 'The alpha-M1 segment of the nicotinic acetylcholine receptor exhibits conformational flexibility in a membrane environment', BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, vol. 1665, pp. 40 - 47, http://dx.doi.org/10.1016/j.bbamem.2004.06.021

Fletcher JI; Swarbrick JD; Maksel D; Gayler KR; Gooley PR, 2002, 'The structure of Ap(4)A hydrolase complexed with ATP-MgFx reveals the basis of substrate binding', STRUCTURE, vol. 10, pp. 205 - 213, http://dx.doi.org/10.1016/S0969-2126(02)00696-2

Tedford HW; Fletcher JI; King GF, 2001, 'Functional Significance of the β-Hairpin in the Insecticidal Neurotoxin ω-Atracotoxin-Hv1a', Journal of Biological Chemistry, vol. 276, pp. 26568 - 26576, http://dx.doi.org/10.1074/jbc.M102199200

Fletcher JI; Dingley AJ; Smith R; Connor M; Christie MJ; King GF, 1999, 'High-resolution solution structure of gurmarin, a sweet-taste- suppressing plant polypeptide', European Journal of Biochemistry, vol. 264, pp. 525 - 533, http://dx.doi.org/10.1046/j.1432-1327.1999.00659.x

Wang XH; Smith R; Fletcher JI; Wilson H; Wood CJ; Howden MEH; King GF, 1999, 'Structure-function studies of ω-atracotoxin, a potent antagonist of insect voltage-gated calcium channels', European Journal of Biochemistry, vol. 264, pp. 488 - 494, http://dx.doi.org/10.1046/j.1432-1327.1999.00646.x

Torres AM; Wang X; Fletcher JI; Alewood D; Alewood PF; Smith R; Simpson RJ; Nicholson GM; Sutherland SK; Gallagher CH; King GF; Kuchel PW, 1999, 'Solution structure of a defensin-like peptide from platypus venom', Biochemical Journal, vol. 341, pp. 785 - 794, http://dx.doi.org/10.1042/0264-6021:3410785

Fletcher JI; Wang X; Connor M; Christie MJ; King GF; Nicholson GM, 1999, 'Spider toxins: A new group of potassium channel modulators', Perspectives in Drug Discovery and Design, vol. 15-16, pp. 61 - 69, http://dx.doi.org/10.1023/A:1017039418046

Fletcher JI; Chapman BE; Mackay JP; Howden MEH; King GF, 1997, 'The structure of versutoxin (δ-atracotoxin-Hv1) provides insights into the binding of site 3 neurotoxins to the voltage-gated sodium channel', Structure, vol. 5, pp. 1525 - 1535, http://dx.doi.org/10.1016/S0969-2126(97)00301-8

Fletcher JI; Smith R; O Donoghue SI; Nilges M; Connor M; Howden MEH; Christie MJ; King GF, 1997, 'The structure of a novel insecticidal neurotoxin, atracotoxin-HVI, from the venom of an Australian funnel web spider', Nature Structural Biology, vol. 4, pp. 559 - 566, http://dx.doi.org/10.1038/nsb0797-559

School of Women's and Children's Health

Dr Jamie Fletcher

Tabs

Study @ WCH

Research @ WCH

Quick Links

Connect